Taxotere Letter to Sanofi-Aventis - Food and Drug Administration
Docetaxel - Wikipedia, the free encyclopedia
It is used mainly for the treatment of breast, ovarian, prostate, and non-small cell lung cancer. Docetaxel has an FDA approved claim for treatment of patients ...
Federal Circuit Affirms Unenforceability of Taxotere Patents | PharmaPatents
9 Apr 2012 ... Federal Circuit Affirms Unenforceability of TAXOTERE Patents ... The district court found that claim 5 of the '561 patent and claim 7 of the '512 ...
Orange Book Blog: Federal Circuit Affirms Unenforceability of TAXOTERE Patents
Aventis Pharma S.A. et al. v. Hospira, Inc. et al., No. 2011-1018 (Fed. Cir.) In a precedential decision earlier this week, the Federal Circuit affirmed a district court decision holding two patents on TAXOTERE (docetaxel), U.S. Patent Nos. 5,750,561 and...
Aitken Klee LLP › CAFC affirms obviousness and unenforceability of Sanofi’s docetaxel (TAXOTERE) formulation patents
9 Apr 2012 ... '512 Claim 7 - A composition comprising a compound of the formula [genus of chemical structures including docetaxel], said composition being ...
Docetaxel- Learn Chemistry
Docetaxel (as generic or under the trade name TAXOTERE) is a
clinically well-established anti-mitotic chemotherapy medication
(that is, it interferes with cell division). It is used mainly for
the treatment of breast, ovarian, prostate, and non-small cell lung
cancer. Docetaxel has an FDA approved claim for treatment of
patients who have locally advanced, or metastatic breast or non
small-cell lung cancer who have undergone anthracycline-based
chemotherapy and failed to stop cancer progression or relapsed and
a European approval for use in hormone-refractory prostate cancer.
According to a 2005 article in the journal Drugs, docetaxel
administered as a one-hour infusion every three weeks generally
over a ten cycle course, docetaxel is considered as or more
effective than doxorubicin, paclitaxel and fluorouracil as a
cytotoxic antimicrotubule agent. Additionally, the optimal
scheduling of docetaxel and other taxenes remains unconfirmed. A
three-week administration schedule used to be and is still
considered effective but new studies are indicating a weekly
schedule might be better. A 2010 article in Current Clinical
WITHDRAWAL ASSESSMENT REPORT FOR Docetaxel Mylan 10 ...
Healthcare resource use in advanced prostate canc... [J Med Econ. 2012] - PubMed - NCBI
PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Outcomes Assessment: Propensity Score Matching With Multi-Level Categories: An Application
The HRQL improvement-related claim for docetaxel + carboplatin treatment arm was mentioned in the section 5.1 of TAXOTERE SmPC, even if no detail of HRQL ...